Balancing the "Faucet" and the "Drain": A Dual-Target Pharmacological Perspective on Fluid Dynamics in High-Altitude Cerebral Edema

High-Altitude Cerebral Edema (HACE) is a potentially fatal microvascular complication caused by severe hypobaric hypoxia. For decades, the pharmacological management of HACE has adopted non-specific systemic drugs to prevent Blood-Brain Barrier (BBB) leakage. However, this classic "leaky faucet" model addresses only part of the neurovascular problem and may overlook the brain's intrinsic "drainage" mechanisms, such as the glymphatic clearance system and cerebral venous compliance. Recent research suggests that hypoxia degrades endothelial tight junctions through autophagy and necroptosis, and may also hinder fluid outflow through the depolarization of aquaporin 4 (AQP4) and venous congestion. From this perspective, a potential pharmacological paradox emerges: acetazolamide, a first-line preventive drug, has been proposed to act as a non-specific inhibitor of AQP4 and could, in theory, attenuate the clearance function of the glymphatic system, although direct clinical evidence for this effect remains limited. We propose a "dual-target" pharmacological strategy that seals the microvascular endothelium and enhances the clearance of glymphatic fluid. Combined with emerging vascular-targeted drugs, nanomedicines, and non-invasive delivery methods, this approach may offer a complementary framework for the prevention and treatment of severe high-altitude-related neurological diseases.